Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

September 30, 2028

Conditions
Prostate Cancer
Interventions
DEVICE

MRI-guided Transurethral Ultrasound Ablation

Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.

Trial Locations (14)

6500

Radboud University Medical Center, Nijmegen

21231

Johns Hopkins Medicine, Baltimore

37232

Vanderbilt University Medical Center, Nashville

46202

Indiana University, Indianapolis

48073

William Beaumont Hospital, Royal Oak

50937

University Hospital of Cologne, Cologne

60637

University of Chicago, Chicago

69120

Universitätsklinikum Heidelberg (University of Heidelberg, Dept of Urology), Heidelberg

90095

University of California Los Angeles, Los Angeles

06520-8058

Yale Cancer Centre, New Haven

75390-9105

University of Texas Southwestern Medical Center, Dallas

N6C 2R5

London Health Sciences Centre, London

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

08029

ResoFus Alomar (Hospital Universitari De Bellvitge), Barcelona

All Listed Sponsors
lead

Profound Medical Inc.

OTHER

NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer | Biotech Hunter | Biotech Hunter